Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat and Venetoclax in R/R NHL
NCT05618366Phase 1Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Jun 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tazemetostat and venetoclax in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Weill Cornell Medicine. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose-Limiting Toxicities at 28 days and 1 more. Started Jun 2023; status: terminated.
02
Drugs
tazemetostatvenetoclax
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05618366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618366.